<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Molina Ramirez SR</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Federal Ministry of Education and Research</funding><pagination>24</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11763500</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>With the goal of fast and accurate diagnosis of infectious diseases, this study presents a novel electrochemical biosensor that employs a refined aptamer (C9t) for the detection of spike (S) protein SARS-CoV-2 variants in a flexible multielectrode aptasensor array with PoC capabilities. Two aptamer modifications were employed: removing the primer binding sites and including two dithiol phosphoramidite anchor molecules. Thus, reducing fabrication time from 24 to 3 h and increasing the stability and sparseness for multi-thiol aptasensors compared to a standard aptasensor using single thiols, without a reduction in aptamer density. The biosensor fabrication, optimization, and detection were verified in detail by electrochemistry, QCM-D, SPR, and XPS. The analyte-receptor binding was further confirmed spectroscopically at the level of individual molecules by AFM-IR. The aptasensor possesses a low limit of detection (8.0 fg/mL), the highest sensitivity reported for S protein (209.5 signal per concentration decade), and a wide dynamic detection range (8.0 fg/mL-38 ng/mL) in nasopharyngeal samples, covering the clinically relevant range. Furthermore, the C9t aptasensor showed high selectivity for SARS-CoV-2 S proteins over biomarkers for MERS-CoV, RSV, and Influenza. Even more, it showed a three times higher sensitivity for the Omicron in comparison to the Wuhan strain (wild type), alpha, and beta variants of the SARS-CoV-2 virus. Those results demonstrate the creation of an affordable and variant-selective refined C9t aptasensor that outperformed current rapid diagnosis tests.</pubmed_abstract><journal>Biosensors</journal><pubmed_title>A Truncated Multi-Thiol Aptamer-Based SARS-CoV-2 Electrochemical Biosensor: Towards Variant-Specific Point-of-Care Detection with Optimized Fabrication.</pubmed_title><pmcid>PMC11763500</pmcid><funding_grant_id>03VP11340</funding_grant_id><funding_grant_id>EXC 2033 - 390677874 - RESOLV</funding_grant_id><pubmed_authors>Martinez-Roque MA</pubmed_authors><pubmed_authors>Catania F</pubmed_authors><pubmed_authors>Offenhausser A</pubmed_authors><pubmed_authors>Molina Ramirez SR</pubmed_authors><pubmed_authors>Mayer D</pubmed_authors><pubmed_authors>Figueroa-Miranda G</pubmed_authors><pubmed_authors>Samiseresht N</pubmed_authors><pubmed_authors>Graef K</pubmed_authors><pubmed_authors>Rabe M</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Truncated Multi-Thiol Aptamer-Based SARS-CoV-2 Electrochemical Biosensor: Towards Variant-Specific Point-of-Care Detection with Optimized Fabrication.</name><description>With the goal of fast and accurate diagnosis of infectious diseases, this study presents a novel electrochemical biosensor that employs a refined aptamer (C9t) for the detection of spike (S) protein SARS-CoV-2 variants in a flexible multielectrode aptasensor array with PoC capabilities. Two aptamer modifications were employed: removing the primer binding sites and including two dithiol phosphoramidite anchor molecules. Thus, reducing fabrication time from 24 to 3 h and increasing the stability and sparseness for multi-thiol aptasensors compared to a standard aptasensor using single thiols, without a reduction in aptamer density. The biosensor fabrication, optimization, and detection were verified in detail by electrochemistry, QCM-D, SPR, and XPS. The analyte-receptor binding was further confirmed spectroscopically at the level of individual molecules by AFM-IR. The aptasensor possesses a low limit of detection (8.0 fg/mL), the highest sensitivity reported for S protein (209.5 signal per concentration decade), and a wide dynamic detection range (8.0 fg/mL-38 ng/mL) in nasopharyngeal samples, covering the clinically relevant range. Furthermore, the C9t aptasensor showed high selectivity for SARS-CoV-2 S proteins over biomarkers for MERS-CoV, RSV, and Influenza. Even more, it showed a three times higher sensitivity for the Omicron in comparison to the Wuhan strain (wild type), alpha, and beta variants of the SARS-CoV-2 virus. Those results demonstrate the creation of an affordable and variant-selective refined C9t aptasensor that outperformed current rapid diagnosis tests.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jan</publication><modification>2025-04-03T23:22:48.941Z</modification><creation>2025-04-03T23:22:48.941Z</creation></dates><accession>S-EPMC11763500</accession><cross_references><pubmed>39852074</pubmed><doi>10.3390/bios15010024</doi></cross_references></HashMap>